AI pharmaceutical company Pathos AI completes $237 million Series E funding round, reaching a post-money valuation of $3 billion

Odaily reports: AI pharmaceutical company Pathos AI has completed a $237 million Series E funding round at a post-money valuation of approximately $3 billion. The round was led by Bristol Myers Squibb, with participation from existing investors. Pathos AI plans to use the new funds to expand its Foundry platform, which leverages thousands of AI agents to assist drug discovery and development, while advancing its four cancer therapeutics currently in clinical stages. (Reuters)